Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30033-x ◽

2016 ◽

Vol 17 (5) ◽

pp. 577-589 ◽

Author(s):

Keunchil Park ◽

Eng-Huat Tan ◽

Ken O'Byrne ◽

Li Zhang ◽

Michael Boyer ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Controlled Trial ◽

Line Treatment ◽

Small Cell Lung ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

10.1016/s0140-6736(21)00228-2 ◽

2021 ◽

Vol 397 (10274) ◽

pp. 592-604 ◽

Author(s):

Ahmet Sezer ◽

Saadettin Kilickap ◽

Mahmut Gümüş ◽

Igor Bondarenko ◽

Mustafa Özgüroğlu ◽

...

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Line Treatment ◽

Small Cell Lung ◽

Phase 3 ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8005 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8005-8005 ◽

Author(s):

Terufumi Kato ◽

Takashi Seto ◽

Makoto Nishio ◽

Koichi Goto ◽

Shinji Atagi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Egfr Mutation ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70184-x ◽

2011 ◽

Vol 12 (8) ◽

pp. 735-742 ◽

Cited By ~ 2256

Author(s):

Caicun Zhou ◽

Yi-Long Wu ◽

Gongyan Chen ◽

Jifeng Feng ◽

Xiao-Qing Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Line Treatment ◽

Small Cell Lung ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30608-3 ◽

2017 ◽

Vol 18 (11) ◽

pp. 1454-1466 ◽

Author(s):

Yi-Long Wu ◽

Ying Cheng ◽

Xiangdong Zhou ◽

Ki Hyeong Lee ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Line Treatment ◽

Small Cell Lung ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12351956.13537054 ◽

2011 ◽

Author(s):

Thomas Stinchcombe

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Line Treatment ◽

Small Cell Lung ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70393-x ◽

2012 ◽

Vol 13 (3) ◽

pp. 239-246 ◽

Cited By ~ 3047

Author(s):

Rafael Rosell ◽

Enric Carcereny ◽

Radj Gervais ◽

Alain Vergnenegre ◽

Bartomeu Massuti ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Line Treatment ◽

Small Cell Lung ◽

Standard Chemotherapy ◽

Phase 3 ◽

First Line Treatment

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

Thoracic Cancer ◽

10.1111/1759-7714.13462 ◽

2020 ◽

Author(s):

Po‐Lan Su ◽

Chian‐Wei Chen ◽

Yi‐Lin Wu ◽

Chien‐Chung Lin ◽

Wu‐Chou Su

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Egfr Mutation ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung Cancer ◽

10.1016/s0169-5002(16)30086-1 ◽

2016 ◽

Vol 91 ◽

pp. S25

Author(s):

K.J. O'Byrne ◽

K. Park ◽

E. Tan ◽

L. Zhang ◽

V. Hirsh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation

Lung Cancer ◽

10.1016/j.lungcan.2015.06.002 ◽

2015 ◽

Vol 90 (1) ◽

pp. 65-70 ◽

Author(s):

Naruo Yoshimura ◽

Shinzoh Kudoh ◽

Shigeki Mitsuoka ◽

Naoki Yoshimoto ◽

Takako Oka ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Phase Ii Study ◽

Combination Regimen ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text